HESI Global shares a new publication by Valentin et al. in Regulatory Toxicology and Pharmacology that revisits ICH S7A after 25 years and explores a modern, risk-based approach to safety pharmacology.
https://doi.org/10.1016/j.yrtph.2026.106096
Join the conversation shaping the future of immune safety assessment!
Register on the event page: hesiglobal.org/event/from-decisions-to-...
Join us April 15–16 for HESI Global’s Benchmark Dose Modeling webinar! Learn from global experts on BMD in tox, epi, ecotox & more—and help advance harmonized risk assessment. Register: https://hesiglobal.org/event/bmd-2026-webinar/
One month left to submit a Letter of Intent for the HESI Global THRIVE Grant Program. THRIVE supports innovative research to predict, prevent, and reduce adverse effects from cancer therapy, with a focus on quality of life for patients and survivors. Details: https://hesithrive.org/guidelines
HESI Global Botanical Safety Consortium paper is a Journal of Applied Toxicology top 10 most-cited article: “Prediction of physicochemical and pharmacokinetic properties of botanical constituents by computational models.” https://doi.org/10.1002/jat.4617
#TopCitedArticle
#WorldHealthDay is a moment to reaffirm that protecting health takes strong science and strong partnerships. HESI Global is proud to collaborate across sectors to advance evidence that supports decisions for human and environmental health.
The HESI Global Cardiac Safety Committee works to reduce unanticipated cardiovascular-related adverse effects from drugs and chemicals and advance innovative approaches for earlier detection, prediction, and understanding of cardiovascular toxicology. Join us! https://connect.hesiglobal.org/RjMboE
💧 The EnviroTox Database, maintained by #HESIGlobal, is one of the largest curated, open-access resources for aquatic toxicity. Whether you're assessing chemical safety or identifying data gaps, this is your go-to platform for advancing ecological risk science.
Dive in: https://envirotoxdatabase.org
The HESI Global Botanical Safety Consortium is working to evaluate the suitability of new approach methodologies, or NAMs, for botanicals as complex mixtures.
View the Fact Sheet to learn more and get involved: https://connect.hesiglobal.org/qmze0Z
Join HESI Global for a webinar with Dr. Rachael Hughes, University of Bristol: A flexible Monte Carlo quantitative bias analysis for unmeasured confounding
🔗 Register on the event page here: hesiglobal.org/event/a-flexible-monte-c...
See HESI Global’s Immuno-Safety Technical Committee (ITC) at #IMMUNOLOGY2026.
Session details, times, and locations are on the HESI Global event page: hesiglobal.org/event/immunology-2026-an...
We hope to see you in Boston!
📢 Time to apply for the 2026 HESI GTTC Professional Development Award!
📆 Application Deadline: May 15, 2026
Learn more and apply here: https://connect.hesiglobal.org/3bqCXK
#HESI #HESIGlobal #GeneticToxicology #Genomics #Toxicology #ProfessionalDevelopment
Better tools for risk assessment start with better science.
The HESI Global eSTAR Committee is working to develop and deliver innovative systems toxicology approaches for risk assessment.
View the eSTAR Committee fact sheet here: https://connect.hesiglobal.org/b25ZrQ
Save the date and join the conversation shaping the future of immune safety assessment!
Registration on the event page: hesiglobal.org/event/from-decisions-to-...
Connect with HESI Global at the Society of Toxicology (SOT) 65th Annual Meeting and ToxExpo!
📍 Check out the full list of HESI Global sessions, speakers and posters here:
https://ow.ly/WXx850YcOPa
Let’s drive the future of safety science—together. #HESIglobal #SOT2026
HESI Global’s March edition of Insights is now available: https://hesiglobal.org/hesi-global-insights-march-2026/
#HESIGlobal #HumanHealth #EnvironmentalHealth #riskassessment #collaboration #SafetyScience
Antibody-Drug Conjugates pose unique nonclinical safety challenges. HESI Global’s ADC Safety Committee advances translational safety evaluation to support better patient outcomes.
Fact sheet: https://connect.hesiglobal.org/C35av8
Join us April 15–16 for HESI Global’s Benchmark Dose Modeling webinar! Learn from global experts on BMD in tox, epi, ecotox & more—and help advance harmonized risk assessment. Register: https://hesiglobal.org/event/bmd-2026-webinar/
Need reference compounds for cardiac safety? HESI Global’s Cardiac Compound Tool is a public, curated list of positive/negative controls with cardiac mechanisms and Cmax data (where available). Explore: https://hesiglobal.org/cctdatabase/
#HESIGlobal #riskassessment #collaboration
🧫 NEW HESI ITC Blog Post: Advancing Immuno-Safety: Complex In Vitro Models in Focus
🔗 https://ow.ly/XITy50YrmwY
Reviewers described this work by the HESI Developmental and Reproductive Toxicology (DART) Committee as a “long overdue contribution” to the field. Barrow et al., 2026. 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝘆𝗶𝗻𝗴 𝗮𝗻𝗱 𝗥𝗲𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗗𝘆𝘀𝘁𝗼𝗰𝗶𝗮 𝗶𝗻 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆 𝗥𝗼𝗱𝗲𝗻𝘁𝘀. Reproductive Toxicology. https://doi.org/10.1016/j.reprotox.2026.109206
The HESI Global Immuno-Safety Technical Committee is pleased to share their latest publication: “𝗙𝗜𝗛 𝗱𝗼𝘀𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗯𝗲𝘆𝗼𝗻𝗱 𝗠𝗔𝗕𝗘𝗟: 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗽𝗵𝗮𝘀𝗲 𝟭 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝘀𝘁𝗮𝗿𝘁𝗶𝗻𝗴 𝗱𝗼𝘀𝗲 𝘄𝗵𝗶𝗹𝘀𝘁 𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘀𝗮𝗳𝗲𝘁𝘆” in Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2026.106038
📢 HESI GTTC Professional Development 2026 Award Cycle: Now Open!
📆 Application Deadline: May 15, 2026
Learn more and apply here: https://connect.hesiglobal.org/3bqCXK
#HESI #HESIGlobal #GeneticToxicology #Genomics #Toxicology #ProfessionalDevelopment
Cancer survival is rising, but fertility can be the cost for young patients. Dr. Shuo Xiao is developing ways to protect ovarian function during cancer therapy. See how HESI THRIVE advances oncofertility survivorship science: https://hesithrive.org/2021-awardee-xiao/
New paper involving HESI Global’s UVCB Committee: in vitro dosing for difficult-to-test substances & hydrocarbon UVCBs. Tips on dosing options, pitfalls, and exposure verification.
Read: https://doi.org/10.1093/etojnl/vgag044
#HESIGlobal #riskassessment #collaboration
DPICT is HESI Global’s open database of peer-reviewed clinical in vivo cell-tracking studies of cell therapy products to assess biodistribution and cell fate.
Explore & Submit your studies: https://dpict-celltracking.org/
#HESIGlobal #CellTherapies #Safety #Tracking #Collaboration
HESI Global’s Genetic Toxicology Technical Committee strengthens interpretation of genetic tox tests for risk-based human health assessment and advances innovative methods. Fact Sheet: https://connect.hesiglobal.org/joRx8o
#HESIGlobal #riskassessment #collaboration
HESI Global GTTC published new evidence to improve nitrosamine (NDSRI) risk evaluation: 79% concordance between Ames & TGR across 33 NDSRIs, supporting stronger science-based decisions that protect patients. https://doi.org/10.1016/j.yrtph.2026.106051 #HESIGlobal #Nitrosamines
📢 Join us April 15–16 for HESI Global’s Benchmark Dose Modeling webinar! Learn from global experts on BMD in tox, epi, ecotox & more—and help advance harmonized risk assessment. 🌍 Register: https://hesiglobal.org/event/bmd-2026-webinar/
eSTAR recognizes Dr. Vicky Wang (Univ. of Ottawa) for leading the 2025 FDA Biomarker Qualification Package for TGx-DDI and co-first authoring the Toxicological Sciences paper—advancing genomic biomarkers for drug safety. #HESIGlobal #eSTAR #TraineeSpotlight #postdoc